Coriolis Pharma appoints Teun van der Heide as CEO

pharmafile.com | November 7, 2026 | Appointment | |  Corporate, biopharmaceutical manufacturing 

Coriolis Pharma has appointed Dr Teun van der Heide as chief executive officer, effective 2 November 2026.

Van der Heide joins the biopharmaceutical contract development and manufacturing organisation (CDMO) with experience in senior commercial and leadership roles at Lonza and ten23 health. At Lonza, he headed the Bioscience Solutions and Capsule Delivery Solutions (Capsugel) business units, before serving as chief business officer at ten23 health, overseeing business development and commercial activities.

In his new role, van der Heide will focus on customer relationships, service quality and business development, with particular emphasis on expanding Coriolis Pharma’s presence in the United States.

Dr Michael Wiggenhorn, co-founder and board member of Coriolis Pharma, said van der Heide’s industry experience and commercial leadership would support the company’s next phase of growth.

He also thanked outgoing CEO Silvia Steyrer-Gruber for her contribution over four and a half years.